Why did Omnicell (OMCL) stock move recently?

On 8/25/2026, Omnicell moved -4.2% — No specific catalyst identified for the decline; Omnicell moved with the broader market or sector amid ongoing post-earnings volatility and valuation concerns noted in recent coverage. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Omnicell (OMCL) overvalued or fairly valued?

MarketChacha shows Omnicell's valuation in context — a trailing P/E of about 34.1, a forward P/E of about 16.5, a price-to-book of about 1.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Omnicell's revenue?

Omnicell reported revenue of $1.2B for FY2025, with net profit of $2.1M, per official filings.

What is the share price of Omnicell (OMCL)?

Omnicell last traded at $34.45 (-1.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Omnicell

OMCL · NYSE · Healthcare · United States

Snapshot

TickerOMCL

ExchangeNYSE

SectorHealthcare

IndustryHealth Information Services

CountryUnited States

Employees3,485

HeadquartersFort Worth, United States

Websitewww.omnicell.com

Filings tracked15

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Who owns it

Insiders2.1%
Institutions97.9%
Public & other0.0%

434 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.58%
Vanguard Portfolio Management LLC6.93%
Wellington Management Group, LLP5.94%
Dimensional Fund Advisors LP5.39%
State Street Corporation4.59%
Vanguard Capital Management LLC4.33%
Millennium Management Llc3.81%
Nomura Asset Management International Inc3.53%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 0.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-1.8% → 0.2%

Margin has expanded by about 1.9 points — the business is getting more profitable.

Return on equity0.2%

Latest ROE of 0.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $310.4M · EPS 0.37

Est. earnings growth -8.1%

Next fiscal year

Rev $1.3B · EPS 2.09

Est. earnings growth -7.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.2B

Net margin

0.2%

ROE

0.2%

Revenue CAGR (2y)

+1.6%

EPS (FY2025)

0.04

Net profit (FY2025)

$2.1M

Ask MarketChacha about OMCL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
No specific catalyst identified for the decline; Omnicell moved with the broader market or sector amid ongoing post-earnings volatility and valuation concerns noted in recent coverage.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.2B	$2.1M	0.04	0.2%	0.2%
FY2024	$1.1B	$12.5M	0.27	1.1%	1.0%
FY2023	$1.1B	$-20.4M	-0.45	-1.8%	-1.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$312.2M	$24.3M	0.52	7.8%
2026Q1	$309.9M	$11.4M	0.25	3.7%
2025Q3	$310.6M	$5.5M	0.12	1.8%
2025Q2	$290.6M	$5.6M	0.12	1.9%
2025Q1	$269.7M	$-7.0M	-0.15	-2.6%
2024Q3	$282.4M	$8.6M	0.19	3.1%
2024Q2	$276.8M	$3.7M	0.08	1.3%
2024Q1	$246.2M	$-15.7M	-0.34	-6.4%
2023Q3	$298.7M	$5.6M	0.12	1.9%
2023Q2	$299.0M	$3.5M	0.08	1.2%
2023Q1	$290.6M	$-15.0M	-0.33	-5.2%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Executive/director change, Exhibits
SEC7/1/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/26/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC4/28/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/5/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC12/8/2025material
10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC10/30/2025material
8-K — Bylaw/charter change, Exhibits
SEC10/6/2025material
8-K — Executive/director change, Exhibits
SEC8/25/2025material
10-Q filing
SEC8/6/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.